Pfizer Inc. EV/EBITDA
Data as of June 01, 2026
EV/EBITDA
7.90
Enterprise Value
$201.16B
EBITDA (TTM)
$25.46B
Sector
Healthcare
How It's Calculated
7.90 = $201.16B ÷ $25.46B
What This Means
Pfizer Inc.'s EV/EBITDA of 7.9 is on the lower side versus many large-cap peers — context still depends on growth and leverage.
About Pfizer Inc.
Pfizer Inc. (PFE) operates in the Healthcare sector, specifically in Drug Manufacturers - General. With a market capitalization of about $149.21B, it ranks as a large-cap stock — a major established company.
Shares recently traded near $26.18, within a 52-week range of $23.06 to $28.75 (-8.9% from the high, +13.5% from the low). Beta of 0.30 indicates relatively lower volatility versus the market.
Trailing profit margin is about 11.8%, signaling a solid profit margin for its industry.
Understanding This Metric
EV/EBITDA is widely used when comparing companies with different debt loads because enterprise value includes net debt while EBITDA approximates operating cash earnings power. For Pfizer Inc., the ratio should be read with growth, capex needs, and cycle position in Healthcare. Pair EV/EBITDA with free cash flow yield and net debt metrics before drawing conclusions — especially when EBITDA is depressed or boosted by one-time items.
Using This Number in Practice
Near 7.90x EV/EBITDA, Pfizer Inc. (PFE) carries a relatively low EV/EBITDA multiple, which may reflect cyclical trough EBITDA, higher perceived risk, or a cash-generative mature profile. Enterprise value of about $201.16B and EBITDA near $25.46B form the ratio — adjust for one-time items before treating the headline multiple as comparable.
Credit and LBO workflows often sort names on EV/EBITDA before drilling into free cash flow and maintenance capex. Pair this view with the EV/EBITDA calculator and the PFE metrics hub for related valuation pages.
Sector Comparison
Among Healthcare names on our S&P 100 coverage, Pfizer Inc.'s EV/EBITDA of 7.90 can be compared with peers such as LLY (28.26), JNJ (16.76), UNH (18.61). Sector context helps interpretation, but each company's growth profile and balance sheet differ — use multiple metrics before drawing conclusions. View all Healthcare stocks.
Key Takeaways
- PFE is grouped in the Healthcare sector for peer comparisons.
- Recent beta of 0.30 suggests lower-than-market price sensitivity.
- Trailing profit margin of 11.8% provides context for how much earnings support the headline multiple.
Related Tools & Guides
Explore calculators and guides connected to this metric, or view all metrics for PFE.
Other PFE Metrics
Frequently Asked Questions
What is PFE's EV/EBITDA?
EV/EBITDA compares enterprise value to operating earnings before interest, taxes, depreciation, and amortization. Pfizer Inc.'s ratio is about 7.90 — common for comparing leveraged companies in Healthcare.
Is 7.90 high or low vs peers?
Among Healthcare peers (e.g. LLY (28.26), TMO (19.75), UNH (18.61)), PFE's 7.90 should be read with growth, capex, and debt levels.
When is EV/EBITDA misleading?
EBITDA ignores capex, working capital, and stock-based comp; negative or tiny EBITDA makes the ratio meaningless. Cross-check with free cash flow and net debt.
Calculate the ev/ebitda for any stock with our free calculator.
Open EV/EBITDA Calculator →